

ROLE OF PHYTOCHEMICALS IN ORAL POTENTIALLY MALIGNANT DISORDERS : A REVIEW

Ananya Madiyal¹, Vidya Ajila², Subhas G Babu³, Shruthi Hedge⁴, Harini Keshavaiah⁵
& Priyadarshini Alva M⁶

^{1,6}Post Graduates, ²Reader, ³Professor & HOD, ^{4,5}Lecturers, Department of Oral Medicine & Radiology, ⁵Department of Periodontics, A.B. Shetty Memorial Institute of Dental Sciences, Nitte University, Mangalore - 575 018, India.

Correspondence :

Ananya Madiyal

Post Graduate, Department of Oral Medicine and Radiology, A.B. Shetty Memorial Institute of Dental Sciences
Nitte University, Mangalore - 575 018, India.

Mobile : +91 95388 40189 E-mail : anyamadiyal@gmail.com

Abstract :

Oral cancer is a major global health concern and poses a challenge to diagnostic and therapeutic aspects of healthcare services. Various oral lesions like leukoplakia, erythroplakia, lichen planus and oral submucous fibrosis categorized as orally potential malignant disorders have shown increased incidence of malignant transformation. Free radicals are highly reactive chemical species with capacity to damage nucleic acids, proteins and lipids and bring about changes of clinical significance. Antioxidants help in scavenging these free radicals and prevent disease progression. Naturally occurring phytochemicals play an important role in preventing oxidative stress and protect the cells from damage by free radicals.

Keywords : Antioxidants, phytochemicals, oral potentially malignant disorders, chemoprevention

Introduction :

Oral cancer is a major global health concern with increasing prevalence and high levels of mortality. It poses a major challenge to diagnostic and therapeutic aspects of the healthcare services. Oral and pharyngeal cancers, grouped together constitute the sixth most common cancer in the world.¹ The annual estimated incidence of oral cancer stands at about 275,000 and pharyngeal cancer at about 130,300, excluding nasopharyngeal cancers in developing countries.² The areas characterised by high incidence rates for oral cancer include South and South-East Asia (Sri Lanka, India, Taiwan and Pakistan), parts of western (France) and Eastern Europe (Hungary, Slovakia and Slovenia), parts of Latin America and the Caribbean (Brazil, Uruguay and Puerto Rico) and in the Pacific regions (Papua

country.³ National Cancer Registry, 2003 identified that the spectrum of the diseases in the country lies in states like Uttar Pradesh, Madhya Pradesh, Bihar, Maharashtra, Gujarat, Andra Pradesh, Karnataka and Tamil Nadu. Variation in incidence depends upon geographic location and adverse habits.

Prognosis of oral cancer is generally poor with a five year survival rate of less than 50%⁴ Local recurrences as well as lymph node metastasis occur in a significant number of the affected people while distant metastasis is often rare. Various oral lesions like leukoplakia, erythroplakia, lichen planus and oral submucous fibrosis are known to have an increased risk of progressing into malignancy. These lesions are collectively termed as 'oral potentially malignant disorders'. WHO in 2005 defined oral potentially malignant disorder as 'the risk of cancer being present in a pre-cancerous lesion or condition, either at the time of initial diagnosis or in the future'⁵ The term conveys that not all of the lesions described under it will turn into cancer but instead, it blankets a family of morphologic alterations that will potentiate some of the lesions into a malignant transformation. WHO first classified oral potentially

Access this article online

Quick Response Code



New Guinea and Melanesia)¹ Oral cancer is one of the most common forms of malignancies in India with a prevalence varying from 11% to 52% of all diagnosed cancers in the

malignant disorders as potentially malignant lesions and potentially malignant conditions (table 1)⁶ in 1978. A classification based on etiology of the lesion was later given by Anthony George et al in 2011 (table 2)⁷

It is a well-established fact that virtually all oral cancers are preceded by visible clinical changes in the oral mucosa usually in the form of red or white patches.⁸ Early diagnosis of these potentially malignant disorders help in avoiding high levels of morbidity and mortality associated with these lesions. Oxidative stress has always been associated with the development of a wide variety of diseases. It is a process derived from the inability of the body's endogenous antioxidant defences to scavenge free radicals. Free radicals are highly reactive chemical species characterized by short half-life and are made up of a single atom or groups of atoms that form a molecule with a free electron.⁹ This electron is responsible for the high reactivity of free radicals. When free radical derived oxidative damage to nucleic acid, proteins and lipids of extra cellular and cellular matrix is observed, it produces damages of clinical importance. Dietary antioxidants can reduce the risk of cancer. Phenolic compounds derived from a variety of fruits and vegetables show anti-inflammatory and anti-cancer effect. Supplements of phytochemicals including carotenoids and flavonoids demonstrate chemopreventive and chemoprotective activity especially in the cellular proliferation phase.

Rationale behind the use of antioxidants in management of oral potentially malignant disorders

Generation of reactive oxygen species by biologic systems either by normal metabolic pathways or as a consequence of exposure to chemical carcinogens contributes to the multi-stage process of carcinogenesis.¹⁰ Some examples of antioxidants include Vitamin C (Ascorbic acid), Vitamin E (Alpha tocopherol), retinol, retinoids and beta-carotene. In 1981 it was discovered that there was an association between low serum beta carotene levels and cancer.¹¹ There exists an inverse relationship between the levels of these antioxidants in the diet and in the serum and the probability of development of cancer.¹² Cancer develops

due to genetic predisposition or due to irreparable oxidative damages to the DNA that cause mutations. Antioxidants are essential in reducing this oxidative stress by scavenging free radicals and thereby reducing mutations, changes in enzyme activity and lipid peroxidation of cellular elements.

Cancer therapeutics mainly concentrates on the final stage of the disease. This limits its preventive potential. Refocus of management of cancer from the end point to the progression of the disease is essential as these interventions will prevent, inhibit and reverse the process of carcinogenesis thereby reducing the long term effects on such individuals. Early detection and treatment of oral potentially malignant disorders will provide a better standard of life to individuals affected by oral cancers.

Phytochemicals

The word phytochemicals is derived from the Greek word 'Phyto' meaning plant. More than 5000 different types of phytochemicals have been identified but they remain just a small percentage of the total number of such plant chemicals. Phytochemicals are defined as 'bioactive non-nutrient plant compounds in fruits, vegetables, grains and other plant foods that have been linked to reducing the risk of major chronic diseases'.¹³

Some of the major phytochemicals are:

1. Beta-carotene

Approximately 16% of the ingested beta-carotene is transformed to retinol by a two-step process in the intestinal mucosa. It is absorbed by the lymphatics and is not taken up by the extra hepatic tissues like bone marrow, blood cells, spleen, adipose tissue, lungs, muscles and kidney.¹⁴ The possible protective effects of beta carotene is attributed to its antioxidant action by trapping free radicals, particularly peroxy and hydroxyl which are involved in aging and carcinogenesis. It also increases cell mediated immune response due to increased monocyte expression and increased response of tumour necrosis factor alpha. Lower than expected levels of serum beta carotene have been seen in men who smoke cigarettes and

consume alcohol. Low levels of beta carotene is associated with increased risk of oral cancer.¹¹ An abundance of beta-carotene has been found in a variety of yellow and green fruits and vegetables.¹³

2. Lycopene

Lycopene is one of the most potent antioxidant and has been hypothesised to prevent carcinogenesis and atherogenesis by protecting critical biomolecules like lipids, lipoproteins and DNA.¹⁵ Lycopene suppresses carcinogen induced phosphorylation of regulatory proteins such as p53 and Rb anti-oncogenes and stops cell division at G₀-G₁ cell cycle phase.¹⁶ It also reduces cellular proliferation induced by potent mitogens like insulin-like growth factors in various cancer cell lines.¹⁷ It exhibits highest physical quenching rate constant with singlet oxygen. Lycopene is a bright red pigment found in tomatoes and other red fruits like red carrots, watermelons and papayas.¹⁸

3. Flavonoids

Flavonoids are a group of plant derived phenolic compounds that have been identified to have antioxidant property to reduce the risk of development of chronic diseases. Flavonoids have an additive effect to the endogenous scavenging systems¹⁹.

They have different functions in the antioxidant system like:

a. Direct Radical Scavenging

Flavonoids stabilize the reactive oxygen species by reacting with the reactive compound of the radical thereby producing a less reactive radical. Few flavonoids directly scavenge superoxide while others scavenge peroxynitrites.²⁰

b. Nitric Oxide

Nitric oxide produced by macrophages reacts with free radicals producing peroxynitrite which can react with low density lipoproteins thereby producing irreversible injury to the cell membrane. Flavonoids scavenge nitric oxide as well as peroxynitrite thus reducing the amount of oxidative damage.²¹

c. Xanthine Oxidase

Xanthine dehydrogenase, an enzyme present under physiologic conditions is changed to xanthine oxidase during ischemic conditions. During reperfusion, xanthine oxidase reacts with molecular oxygen thereby producing superoxide free radicals. Flavonoids scavenge these superoxide molecules thus resulting in less oxidative injury.²²

d. Leukocyte Immobilization

During ischemia and inflammation, leukocytes which are freely moving along the endothelial wall are acted upon by endothelium derived mediators and complement factors and adhere to the endothelial wall and stimulate degranulation of neutrophils. Flavonoids cause a decrease in the number of immobilized leukocytes and total serum complement. They also cause a decrease in the degranulation of neutrophils and mast cells and provide a protective action during reperfusion by modulation of receptor directed calcium channels in the plasma membrane.²³

One of the best described group of flavonoids, quercetin is found in abundance in onions, apples, broccoli and berries. The second group, narigin is found in citrus fruits. Flavonoids belonging to the catechin group are found primarily in green and black tea as well as in red wine. The last group of flavonoids, anthocyanins are found in strawberries, grapes, wine and tea.^{18, 24}

Role of phytochemicals in the prevention of cancer

Free radicals are constantly produced in the body as a result of normal metabolic processes. The key to maintaining health is achieving a balance between free radicals and antioxidants. Over production of free radicals causes oxidative damage to cell membrane lipids, proteins and DNA leading to cancer production. To prevent or slow down the oxidative stress induced by free radicals, sufficient amounts of antioxidants should be consumed. Phytochemicals like carotenoids and flavonoids help to prevent cellular systems from oxidative stress and may also lower the risk of chronic disease.¹³ Phytochemicals have a complementary and overlapping mechanism of action like

scavenging of free radicals, regulation of gene expression in cell proliferation and differentiation, inhibition of expression of oncogenes, induction of tumor suppressor gene expression, modulation of enzyme activity in detoxification and regulation of hormone metabolism.^{25,26}

Natural phytochemicals present in fruits and vegetables have strong antioxidant and anti-proliferative activities. The synergistic effect of various phytochemicals is responsible for its beneficial effect. Individual antioxidants produce varying degrees of tumor regression only at very high doses which is frequently associated with toxicity. At lower doses they may be ineffective or stimulate the growth of tumour cells.²⁷ Therefore the use of a single antioxidant has no therapeutic or clinical significance. Protection against free radicals can be enhanced by consuming a mixture of dietary antioxidants thereby avoiding the toxicity associated with high doses or growth stimulation associated with low doses.

Antioxidants in therapeutics of oral lesions

In general, pre-malignant lesions are not lethal by themselves and are associated with low risk of malignant transformation. The goal of cancer therapeutics is not only treatment of cancer but also the suppression and reversal of pre-malignant lesions. The possible use of antioxidants in oral mucosal lesions include the following:²⁷

1. Prevention of lesions in high risk individuals with mucosa that clinically appears normal with no history of pre-malignant or malignant lesion.
2. Treatment of pre-malignant oral lesions.
3. In patients who had pre-malignant or malignant lesions that have been successfully treated, in order to prevent recurrence of the treated initial lesion or to prevent the development of a secondary or a separate primary.

Non-surgical management of pre-cancerous lesions should be considered, especially if they involve a large surface area and in medically compromised patients. It also provides additional advantages of being non-invasive, relatively cost effective and ease of application. Patients with dermatologic disorders receive doses of beta-carotene as

high as 300 mg per day for years with only carotenoderma as a side effect. Clinical trials use doses considerably less than 300 mg per day as beta-carotene levels are minimally elevated when the dose is substantially increased and the possibility of carotenoderma is reduced.²⁸ There was absence of side effects in patients supplemented with 26-120 mg of beta-carotene per day.²⁹ A combination of beta-carotene with vitamin A or retinoids has showed some success in the treatment of oral leukoplakia.³⁰ Alpha-tocopherol in doses as high as 3200 mg per day have been well tolerated by adults without any signs of toxicity.³¹ Supplements are more effective in achieving high plasma alpha-tocopherol levels than diet modifications. It plays an important role in protecting the cell membranes from lipid peroxidation. Administration of 800 IU of alpha-tocopherol per day for 24 weeks shows some clinical response in patients with oral potentially malignant disorders.³¹ 16 mg of lycopene in divided doses has shown improvement in mouth opening and burning sensation in patients with oral submucous fibrosis.¹⁸ Oral supplementation of 4-8 mg of lycopene given over a period of eight months showed significant reduction in hyperkeratosis in patients with oral leukoplakia with no clinical signs of toxicity.³²

A practical strategy for people who want to optimize their health through diet modification is by increasing the consumption of fruits, vegetables and whole grains that are rich in antioxidants. A combination of orange, apple, grape and blueberry has displayed a synergistic effect in delivering these antioxidants in sufficient quantities. The phytochemicals present in food differ in their molecular size, polarity and solubility which may affect their bioavailability and distribution in various macromolecules, subcellular organelles, cells, organs and tissues. This synergistic and additive effect of whole foods has been proposed to be responsible for their potent antioxidant and anticancer effects.¹³

Summary:

Normal metabolic processes produce free radicals in the body. This mechanism is accentuated in the presence of precipitating factors such as smoking or alcohol

Table 1

Potentially Malignant Disorders	Potentially Malignant Lesions
Oral submucous fibrosis	Leukoplakia
Actinic keratosis	Erythroplakia
Lichen planus	Palatal lesions in reverse smokers
Discoid lupus erythematosus	

Table 2

High risk	Lifestyle related	Infections	Immunodeficiency	Inherited disorders
Leukoplakia	Smokeless tobacco keratosis	Hyperplastic candidiasis	Solid organ transplantation	Xeroderma pigmentosa
Erythroplakia	Reverse smoker's palate	Viral (HPV, HIV, EBV, HBV, HSV)	Graft versus host disease	Dyskeratosis congenita
Oral submucous fibrosis	Actinic cheilitis	Tertiary syphilis	Chronic cutaneous lupus erythematosus	Epidermolysis bullosa
Erosive lichen planus				Bloom syndrome
				Fanconi's anemia

consumption. This causes generation of excess of free radicals. A balance between oxidative free radicals and antioxidants is maintained in the body by oxygen scavengers. In cases where there is an excess of free radical production, these scavenging systems are overwhelmed and fail to reduce the oxidative stress. This causes damage to the cell membrane phospholipids and cell organelles and is termed as oxidative damage. Pre-cancer, cancer and other chronic diseases are mainly caused as a result of this oxidative damage. Use of antioxidant supplements shows promise in the resolution of such potentially malignant disorders.

Phytochemicals show a synergistic function when supplemented along with other antioxidants. Use of a single antioxidant at levels that can suppress or cause regression of pre-malignant lesions may produce features of toxicity like carotenoderma and hypervitaminosis. Hence a combination of various antioxidants should be used for the treatment of such disorders. Before making the decision to use antioxidants for treatment, it is critical to obtain histopathologic diagnosis of the lesion. Lesions diagnosed as hyperkeratotic will take considerable amount of time before showing clinical signs of improvement while lesions diagnosed as dysplastic may not show any positive

change. Newer analogues of synthetic retinoic acid show better efficacy of treatment with less instances of toxicity. While surgical management remains the mainstay of treatment of oral potentially malignant disorders, use of antioxidants, particularly newer analogues are gaining importance as non-invasive treatment options. Chemoprevention with these agents is useful in advanced disease or in an adjuvant setting in combination with surgical management, steroid hormones and cytotoxic chemotherapy that are currently available as treatment for patients with oral potentially malignant disorders.

No single antioxidant can replace the health benefits of a diet with a complex mixture of phytochemicals derived from a combination of various fruits, vegetables and whole grains. Phytochemical extracts from such fruits and vegetables have strong antioxidant and antiproliferative effects and a major part of the total antioxidant activity is from the combination of these phytochemicals. Diet modifications along with dietary supplements, nutraceuticals and functional foods can help prevent the development and progression of diseases like cancer. Further research on the health benefits, efficacy and safety of phytochemicals in whole foods is warranted.

References :

1. Warnakulasuriya S. Global epidemiology of oral and pharyngeal cancer. *Oral Oncology* 2009; 45: 309-16.
2. Ferley J, Parkin DM. GLOBOCAN 2002. Cancer incidence, Mortality and Prevalence Worldwide. IARC Cancer Base (2002 estimates). Lyon IARC press 2004.
3. Tuyns AJ, Hiramaya T. World Health Organisation Epidemiologic Studies of the Tumors of the Mouth and Jaw. *J Dent Res* 1966; 45: 535-45.
4. Melhotra R, Pandya S, Chaudary AK, Kumar M, Singh M. Prevalence of Oral Pre-malignant and Malignant Lesions at a Tertiary Level Hospital in Allahabad, India. *Asian Pacific J Cancer Prev* 2008; 9: 263-6.
5. Warnakulasuriya S, Johnson NW, van der Waal I. Nomenclature and Classification of Potentially Malignant Disorders of the Oral Mucosa. *J Oral Pathol Med* 2007; 36: 575-80.
6. World Health Organization Collaborating Centre for Oral Precancerous Lesions. Definition of leukoplakia and related lesions: an aid to studies on oral precancer. *Oral Surg Oral Med Oral Pathol* 1978; 46: 518-39.
7. George A, Sreenivasan B, Sunil S, Varghese S, Thomas J, Gopakumar D, Varghese M. Potentially Malignant Disorders of Oral Cavity. *OMPJ* 2011; 2: 95-100.
8. Reibel J. Prognosis of Oral Pre-malignant Lesions: Significance of Clinical, Histopathological and Molecular Biological Characteristics. *Crit Rev Oral Biol Med* 2003; 14: 47-62.
9. Iannitti T, Rottigni V, Palmieri B. Role of Free Radicals and Antioxidant Defences in Oral Cavity-Related Pathologies. *J Oral Pathol Med* 2012; 649-61.
10. Khan SG, Katiyar SK, Agarwal R, Mukhtar H. Enhancement of Antioxidant and Phase II Enzymes by Oral Feeding of Green Tea Polyphenols in Drinking Water to SKH-1 Hairless Mice: Possible Role in Cancer Chemoprevention. *Cancer Res* 1992; 52: 4050-2.
11. Peto R, Doll R, Buckley JD, Sporn MB. Can Dietary Beta-carotene Materially Reduce Cancer Rates? *Nature* 1981; 290: 201-8.
12. Gaby SK, Bendich A, Singh VN, Machlin LJ (eds.) *Vitamin Intake and Health*. New York: Marcel Dekker 1991; 17-27.
13. Rui Hai Liu. Potential Synergy of Phytochemicals in Cancer Prevention: Mechanism of Action. *J Nutr* 2004; 134: 34795-855.
14. Kaugras EG, Silverman S, Lovas JGL, Thompson JS, Brandt RB, Singh VN. Role of Antioxidant Supplements in the Treatment of Human Oral Leukoplakia. *Oral Surgery Oral Medicine Oral Pathology* 1996; 81: 5-14.
15. Agarwal S, Rao AV. Tomato Lycopene and Low Protein Lipoprotein Oxidation: A Human Dietary Intervention Study. *Lipids* 1998; 33: 981-4.
16. Matsushima NR, Shidoji Y, Nishiwaki S, Yamada T, Moriwaki H, Muto Y. Suppression by carotenoids of microcystin-induced morphological changes in mouse hepatocytes. *Lipids* 1995; 30: 1029-34.
17. Levy J, Bosin E, Feldman B, Giat Y, Miinster A, Danilenko M, Sharoni Y. Lycopene is a More Potent Inhibitor of Human Cancer Cell Proliferation than Either Alpha-carotene or Beta-carotene. *Nutr Cancer* 1995; 24: 257-66.
18. Sunderraj S, Sharma R, Agarwal V, Narang P, Reddy YG, Sharma AK. An In vivo Study to Determine the Efficacy of Lycopene as Compared to Multi-vitamin Preparation in the Treatment of Oral Sumucus Fibrosis. *J Indian Aca Oral Med Radiol* 2012; 24: 190-3.
19. Nijveldt RJ, van Nood E, van Hoorn DEC, Boelens PG, van Norren K, van Leeuwen PAM. Flavonoids: A Review of Probable Mechanism of Action and Potential Applications. *Am J Clin Nutr* 2001; 74: 418-25.
20. Korkina LG, Afanas'ev IB. Antioxidant and Chelating Properties of Flavonoids. *Adv Pharmacol* 1997; 38: 151-63.
21. van Acker SA, Tromp MN, Haenen GR, van der Vijgh WJ, Bast A. Flavonoids as Scavengers of Nitric Oxide Radical. *Biochem Biophys Res Commun* 1995; 214: 755-9.
22. Chang WS, Lee YJ, Lu FJ, Chiang HC. Inhibitory Effects of Flavonoids on Xanthine Oxidase. *Anticancer Res* 1993; 13: 2165-70.
23. Bennett JP, Gomperts BD, Wollenweber E. Inhibitory Effects of Natural Flavonoids on Secretion from Mast Cells and Neutrophils. *Arzneimittelforschung* 1981; 31: 433-7.
24. de Ghroot H, Rauen U. Tissue Injury by Reactive Oxygen Species and the Protective Effects of Flavonoids. *Fundam Clin Pharmacol* 1998; 12: 249-55.
25. Dragsted LO, Strube M, Larsen JC. Cancer-protective Factors in Fruits and Vegetables: Biochemical and Biological Background. *Pharmacol Toxicol* 1993; 72: 116-35.
26. Waladkhani AR, Clemens MR. Effect of Dietary Phytochemicals on Cancer Development. *Int J Mol Med* 1998; 1: 747-53.
27. Shetti A, Keluskar V, Aggarwal A. Antioxidants: Enhancing Oral and General Health. *JIAOMR* 2009; 21: 1-6.
28. Kaugras EG, Silverman S, Lovas JGL. A Clinical Trial of Antioxidant Supplements in the Treatment of Oral Leukoplakia. *Oral Surg Oral Med Oral Path* 1994; 78: 462-8.
29. Mathews-Roth MM. Beta-carotene: Clinical Aspects. In: *New Protective Roles for Selected Nutrients*. Alan R Liss 1989; 17-38.
30. Stich HF, Rosin MP, Hornby AP. Remission of Oral Leukoplakias and Micronuclei in the Tobacco/betel Nut Quid Chewers Treated with Beta-carotene and with Beta-carotene plus Vitamin A. *Int J Cancer* 1988; 42: 195-9.
31. Benner SE¹, Winn RJ, Lippman SM, Poland J, Hansen KS, Luna MA, Hong WK. Regression of Oral Leukoplakia with Alpha-tocopherol: A Community Clinical Oncology Program Chemoprevention Study. *J Natl Cancer Inst* 1993; 85: 44-7.
32. Singh M, Krishnappa R, Bagewadi A, Keluskar V. Efficacy of Oral Lycopene in the Treatment of Oral Leukoplakia. *Oral Oncology* 2004; 40: 591-6.